Elimination of protein aggregates prevents premature senescence in human trisomy 21 fibroblasts

PLoS One. 2019 Jul 29;14(7):e0219592. doi: 10.1371/journal.pone.0219592. eCollection 2019.

Abstract

Chromosome abnormalities induces profound alterations in gene expression, leading to various disease phenotypes. Recent studies on yeast and mammalian cells have demonstrated that aneuploidy exerts detrimental effects on organismal growth and development, regardless of the karyotype, suggesting that aneuploidy-associated stress plays an important role in disease pathogenesis. However, whether and how this effect alters cellular homeostasis and long-term features of human disease are not fully understood. Here, we aimed to investigate cellular stress responses in human trisomy syndromes, using fibroblasts and induced pluripotent stem cells (iPSCs). Dermal fibroblasts derived from patients with trisomy 21, 18 and 13 showed a severe impairment of cell proliferation and enhanced premature senescence. These phenomena were accompanied by perturbation of protein homeostasis, leading to the accumulation of protein aggregates. We found that treatment with sodium 4-phenylbutyrate (4-PBA), a chemical chaperone, decreased the protein aggregates in trisomy fibroblasts. Notably, 4-PBA treatment successfully prevented the progression of premature senescence in secondary fibroblasts derived from trisomy 21 iPSCs. Our study reveals aneuploidy-associated stress as a potential therapeutic target for human trisomies, including Down syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aneuploidy
  • Cell Proliferation / drug effects
  • Cellular Senescence* / drug effects
  • Energy Metabolism / drug effects
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Fibroblasts / pathology*
  • Glucose / metabolism
  • Humans
  • Induced Pluripotent Stem Cells / drug effects
  • Induced Pluripotent Stem Cells / metabolism
  • Lactates / metabolism
  • Mitochondria / drug effects
  • Mitochondria / pathology
  • Oxidative Stress / drug effects
  • Phenylbutyrates / pharmacology
  • Protein Aggregates* / drug effects
  • RNA / metabolism
  • Trisomy / genetics
  • Trisomy / pathology*

Substances

  • Lactates
  • Phenylbutyrates
  • Protein Aggregates
  • RNA
  • 4-phenylbutyric acid
  • Glucose

Grants and funding

This work was supported by the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED) (JP18bm0804009 to Y.K.) and JSPS KAKENHI (JP16K10090 to Y.K.). This work was also supported by the grants from Mitsui Life Social Welfare Foundation, and Shionogi & Co., Ltd. Additionally, Tokiwa-Bio, Inc. provided support in the form of salary for author MN, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.